Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of $72.33 million. The enterprise value is -$154.94 million.

Market Cap	72.33M
Enterprise Value	-154.94M

Important Dates

The last earnings date was Thursday, May 8, 2025, after market close.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Sutro Biopharma has 84.46 million shares outstanding. The number of shares has increased by 35.16% in one year.

Current Share Class	84.46M
Shares Outstanding	84.46M
Shares Change (YoY)	+35.16%
Shares Change (QoQ)	+0.72%
Owned by Insiders (%)	1.56%
Owned by Institutions (%)	53.51%
Float	65.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.02
Forward PS	2.22
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.16

Current Ratio	2.16
Quick Ratio	1.97
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.82

Financial Efficiency

Return on equity (ROE) is -679.15% and return on invested capital (ROIC) is -235.59%.

Return on Equity (ROE)	-679.15%
Return on Assets (ROA)	-39.55%
Return on Invested Capital (ROIC)	-235.59%
Return on Capital Employed (ROCE)	-121.74%
Revenue Per Employee	$214,303
Profits Per Employee	-$791,019
Employee Count	310
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

In the past 12 months, Sutro Biopharma has paid $2.36 million in taxes.

Income Tax	2.36M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -78.54% in the last 52 weeks. The beta is 1.71, so Sutro Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.71
52-Week Price Change	-78.54%
50-Day Moving Average	0.82
200-Day Moving Average	2.25
Relative Strength Index (RSI)	47.29
Average Volume (20 Days)	928,463

Short Selling Information

The latest short interest is 6.86 million, so 8.12% of the outstanding shares have been sold short.

Short Interest	6.86M
Short Previous Month	5.34M
Short % of Shares Out	8.12%
Short % of Float	10.42%
Short Ratio (days to cover)	2.95

Income Statement

In the last 12 months, Sutro Biopharma had revenue of $66.43 million and -$245.22 million in losses. Loss per share was -$2.98.

Revenue	66.43M
Gross Profit	54.82M
Operating Income	-229.33M
Pretax Income	-97.16M
Net Income	-245.22M
EBITDA	-221.98M
EBIT	-229.33M
Loss Per Share	-$2.98

Full Income Statement

Balance Sheet

The company has $248.97 million in cash and $21.40 million in debt, giving a net cash position of $227.58 million or $2.69 per share.

Cash & Cash Equivalents	248.97M
Total Debt	21.40M
Net Cash	227.58M
Net Cash Per Share	$2.69
Equity (Book Value)	-25.81M
Book Value Per Share	-0.31
Working Capital	154.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$194.68 million and capital expenditures -$3.83 million, giving a free cash flow of -$198.51 million.

Operating Cash Flow	-194.68M
Capital Expenditures	-3.83M
Free Cash Flow	-198.51M
FCF Per Share	-$2.35

Full Cash Flow Statement

Margins

Gross Margin	82.52%
Operating Margin	-345.20%
Pretax Margin	-365.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-35.16%
Shareholder Yield	-35.16%
Earnings Yield	-337.59%
FCF Yield	-273.29%

Analyst Forecast

The average price target for Sutro Biopharma is $5.47, which is 538.72% higher than the current price. The consensus rating is "Hold".

Price Target	$5.47
Price Target Difference	538.72%
Analyst Consensus	Hold
Analyst Count	7
Revenue Growth Forecast (5Y)	-2.38%
EPS Growth Forecast (5Y)	-50.08%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sutro Biopharma has an Altman Z-Score of -4.89 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.89
Piotroski F-Score	1